Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

de Bruin, 2021, Clinical features and prognostic factors in Covid-19: a prospective cohort study, eBioMedicine, 67, 10.1016/j.ebiom.2021.103378 Wiersinga, 2020, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA, 324, 782, 10.1001/jama.2020.12839 Docherty, 2020, Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study, BMJ, 369 Afzali, 2022, The state of complement in COVID-19, Nat Rev Immunol, 22, 77, 10.1038/s41577-021-00665-1 Carvelli, 2020, Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis, Nature, 588, 146, 10.1038/s41586-020-2600-6 Aiello, 2022, C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19, Blood Adv, 6, 866, 10.1182/bloodadvances.2021005246 Vlaar, 2020, Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial, Lancet Rheumatol, 2, e764, 10.1016/S2665-9913(20)30341-6 Vlaar, 2022, The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19, Clin Transl Sci, 15, 854, 10.1111/cts.13213 Jansen, 2007, Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not?, Intensive Care Med, 33, 894, 10.1007/s00134-007-0580-8 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006 Ranieri, 2012, Acute respiratory distress syndrome: the Berlin definition, JAMA, 307, 2526 Gordon, 2022, Interleukin-6 receptor antagonists in critically ill patients with COVID-19, N Engl J Med, 327, 1247 Shankar-Hari, 2021, Association between administration of il-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis, JAMA, 326, 499, 10.1001/jama.2021.11330 Rosas, 2021, Tocilizumab in hospitalized patients with severe COVID-19 pneumonia, N Engl J Med, 384, 1503, 10.1056/NEJMoa2028700 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 Shah, 2022, In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality, Ann Intern Med, 175, 10.7326/J22-0033 Annane, 2020, Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study, eClinicalMedicine, 28, 10.1016/j.eclinm.2020.100590 Sun, 2015, Treatment with anti-c5a antibody improves the outcome of H7N9 virus infection in African green monkeys, Clin Infect Dis, 60, 586, 10.1093/cid/ciu887 Lim, 2021, Complement inhibition in severe COVID-19—blocking C5a seems to be key, eClinicalMedicine, 35, 10.1016/j.eclinm.2021.100722 Riedemann, 2017, Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition, Clin Immunol, 180, 25, 10.1016/j.clim.2017.03.012 Cyprian, 2021, Complement C5a and clinical markers as predictors of COVID-19 disease severity and mortality in a multi-ethnic population, Front Immunol, 12, 10.3389/fimmu.2021.707159 Thomas, 2021, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months, N Engl J Med, 385, 1761, 10.1056/NEJMoa2110345 Hilty, 2022, mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland, Intensive Care Med, 48, 362, 10.1007/s00134-021-06610-z Pocock, 2016, The nature of the p value, N Engl J Med, 375, 2205, 10.1056/NEJMc1612970